Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Conestoga Mid Cap Composite Conestoga Capital Advisors, LLC | “Although Merit Medical reported solid organic revenue and EBITDA growth, the manager highlights tariff headwinds in China as a key challenge that led to a downward revision of 2025 EPS guidance. The company hopes to offset less than half of this headwind through operational efficiencies.” | BEAR | Q2 2025 Jun 30, 2025 | View Pitch |
Carillon Eagle Small Cap Growth Fund Eric Mintz, Christopher Sassouni, David Cavanaugh | “Merit Medical Systems designs, manufactures, and markets single-use medical devices for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, and endoscopy. The stock lagged due largely to tariff concerns following the Liberation Day announcement, impacting sentiment given its global footprint and exposure to China. While earnings results beat expectations, earnings per share (EPS) guidance was lowered due to increased tariff-related costs. Management expects to mitigate about half of this impact by 2026 through manufacturing and operational initiatives. Despite this near-term margin pressure, we believe nothing has fundamentally changed with the company as it continues to exceed revenue guidance. We remain confident in the company's long-term outlook. BSD Analysis: Merit Medical is a steady performer in minimally invasive medical devices, with a portfolio that spans cardiology, oncology, and diagnostic intervention. The company wins by being reliable, specialized, and deeply embedded in clinician workflows. Innovation tends to be incremental rather than flashy, but that's exactly what hospitals want for procedural consistency. Margin expansion efforts are paying off as manufacturing consolidation and product mix improve profitability. International growth is accelerating, providing another leg of support. The business is sticky because switching devices in procedural medicine is costly and risky for hospitals. Merit isn't a hype-driven medtech name, but its consistency makes it a compelling compounder.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Merit Medical Systems delivers single-use medical devices and has successfully translated high single-digit revenue growth into stronger earnings through margin improvement efforts. Additionally, a newly FDA-approved hemodialysis device provides clear growth visibility into 2026 and 2027. Despite these strong dynamics, the fund reduced its position to lock in profits after a period of strong performance.” | BULL | Q1 2025 Mar 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
